Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy

doi:10.3748/wjg.v21.i8.2568

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 8

This Article

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7772)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

470

WORD

303

HTML

3934

Figures (1-4)

464

Sum=5171

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1188

Download

1416

Sum=2604

Feb 28, 2015 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Gastroenterol. Feb 28, 2015; 21(8): 2568-2572
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2568

Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy

Jung Gil Park, Soo Young Park, Hye Won Lee

Jung Gil Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, CHA University, Gumi CHA Medical Center, Gumi 730-728, South Korea

Soo Young Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 700-721, South Korea

Hye Won Lee, Department of Pathology, School of Medicine, Kyungpook National University, Daegu 700-721, South Korea

Author contributions: Park JG designed the report and collected the patient’s clinical data; Park SY performed the radiofrequency ablation; Lee HW analyzed histology and created histologic figure; Park JG and Park SY wrote the paper.

Correspondence to: Soo Young Park, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 700-721, South Korea. psyoung0419@gmail.com

Telephone: +82-53-2005519 Fax: +82-53-4268773

Received: September 14, 2014
Peer-review started: September 15, 2014
First decision: October 14, 2014
Revised: October 18, 2014
Accepted: November 11, 2014
Article in press: November 11, 2014
Published online: February 28, 2015
Processing time: 166 Days and 18.7 Hours

Abstract

Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC). Though sorafenib has proven its efficacy in advanced stage HCC, there are limited reports on the role of sorafenib allowing for curative treatment by down-staging. We herein report a case of advanced HCC with vascular invasion, which showed treatment response by sorafenib therapy as to allow for radiofrequency ablation as curative treatment. The patient was followed-up for 6 mo without recurrence with continued sorafenib therapy.

Keywords: Hepatocellular carcinoma; Radiofrequency ablation; Sorafenib; Down-staging; Complete remission

Core tip: Though sorafenib is well known to efficacy in advanced hepatocellular carcinoma (HCC), the consensus of its role as down-staging is limited. Depending on response after sorafenib therapy, active strategy should be needed to offer chance for cure in advanced stage HCC.